CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia

T-cell prolymphocytic leukemia (T-PLL) is a poor prognostic disease with very limited options of efficient therapies. Most patients are refractory to chemotherapies and despite high response rates after alemtuzumab, virtually all patients relapse. Therefore, there is an unmet medical need for novel...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Biomark Res
Autors principals: Cuesta-Mateos, Carlos, Fuentes, Patricia, Schrader, Alexandra, Juárez-Sánchez, Raquel, Loscertales, Javier, Mateu-Albero, Tamara, Vega-Piris, Lorena, Espartero-Santos, Marina, Marcos-Jimenez, Ana, Sánchez-López, Blanca Andrea, Pérez-García, Yaiza, Jungherz, Dennis, Oberbeck, Sebastian, Wahnschaffe, Linus, Kreutzman, Anna, Andersson, Emma I., Mustjoki, Satu, Faber, Edgar, Urzainqui, Ana, Fresno, Manuel, Stamatakis, Kostantino, Alfranca, Arantzazu, Terrón, Fernando, Herling, Marco, Toribio, María Luisa, Muñoz-Calleja, Cecilia
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Rapid Communication
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7585232/
https://ncbi.nlm.nih.gov/pubmed/33110606
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-020-00234-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars